Next Article in Journal
Sickle Cell Disease—Genetics, Pathophysiology, Clinical Presentation and Treatment
Next Article in Special Issue
Validation of a Fast, Robust, Inexpensive, Two-Tiered Neonatal Screening Test algorithm on Dried Blood Spots for Spinal Muscular Atrophy
Previous Article in Journal
Newborn Screening for Selected Disorders in Nepal: A Pilot Study
Previous Article in Special Issue
The Importance of Assay Imprecision near the Screen Cutoff for Newborn Screening of Lysosomal Storage Diseases
Open AccessArticle

Including Classical Galactosaemia in the Expanded Newborn Screening Panel Using Tandem Mass Spectrometry for Galactose-1-Phosphate

Danish Center for Newborn Screening, Statens Serum Institut, 2300 Copenhagen, Denmark
Centre for Inherited Metabolic Diseases, Departments of Paediatrics and Clinical Genetics, Copenhagen University Hospital, 2100 Copenhagen, Denmark
Author to whom correspondence should be addressed.
Int. J. Neonatal Screen. 2019, 5(2), 19;
Received: 29 March 2019 / Revised: 23 April 2019 / Accepted: 2 May 2019 / Published: 4 May 2019
(This article belongs to the Special Issue Selected Papers from 11th ISNS European Regional Meeting)
Galactosaemia has been included in various newborn screening programs since 1963. Several methods are used for screening; however, the predominant methods used today are based on the determination of either galactose-1-phosphate uridyltransferase (GALT) activity or the concentration of total galactose. These methods cannot be multiplexed and therefore require one full punch per sample. Since the introduction of mass spectrometry in newborn screening, many diseases have been included in newborn screening programs. Here, we present a method for including classical galactosaemia in an expanded newborn screening panel based on the specific determination of galactose-1-phosphate by tandem mass spectrometry. The existing workflow only needs minor adjustments, and it can be run on the tandem mass spectrometers in routine use. Furthermore, compared to the currently used methods, this novel method has a superior screening performance, producing significantly fewer false positive results. We present data from 5500 routine newborn screening samples from the Danish Neonatal Screening Biobank. The cohort was enriched by including 14 confirmed galactosaemia positive samples and 10 samples positive for other metabolic disorders diagnosed through the Danish newborn screening program. All galactosaemia positive samples were identified by the method with no false positives. Furthermore, the screening performance for other metabolic disorders was unaffected. View Full-Text
Keywords: galactosaemia; mass spectrometry; newborn screening; GALT galactosaemia; mass spectrometry; newborn screening; GALT
Show Figures

Figure 1

MDPI and ACS Style

Cohen, A.S.; Baurek, M.; Lund, A.M.; Dunø, M.; Hougaard, D.M. Including Classical Galactosaemia in the Expanded Newborn Screening Panel Using Tandem Mass Spectrometry for Galactose-1-Phosphate. Int. J. Neonatal Screen. 2019, 5, 19.

Show more citation formats Show less citations formats
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

Back to TopTop